American International Group, Inc. Ventyx Biosciences, Inc. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.9 - $10.13 $376 - $2,005	-198 Reduced 0.85%	23,064 $126,000
Q4 2023 Feb 13, 2024	SELL	$2.08 - $31.18 $197 - $2,962	-95 Reduced 0.41%	23,262 $57,000
Q3 2023 Nov 13, 2023	BUY	$29.8 - $40.3 $24,763 - $33,489	831 Added 3.69%	23,357 $811,000
Q2 2023 Aug 04, 2023	BUY	$28.53 - $39.55 $299,308 - $414,919	10,491 Added 87.17%	22,526 $738,000
Q1 2023 May 12, 2023	BUY	$29.51 - $46.65 $7,082 - $11,196	240 Added 2.03%	12,035 $403,000
Q4 2022 Feb 10, 2023	BUY	$24.16 - $36.38 $27,880 - $41,982	1,154 Added 10.84%	11,795 $386,000
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $1,908 - $5,843	151 Added 1.44%	10,641 $371,000
Q2 2022 Aug 12, 2022	BUY	$11.95 - $18.75 $63,394 - $99,468	5,305 Added 102.31%	10,490 $128,000
Q1 2022 May 13, 2022	SELL	$10.0 - $19.98 $3,660 - $7,312	-366 Reduced 6.59%	5,185 $70,000
Q4 2021 Feb 11, 2022	BUY	$14.2 - $23.07 $78,824 - $128,061	5,551 New	5,551 $110,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.